Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some claims match label-supported concepts (pain/antipyretic/anti-inflammatory properties, mechanism involving prostaglandin synthesis and mediators of inflammation). However, multiple key labeling elements are missing or not supported by the provided label excerpts (exact indications beyond pain and primary dysmenorrhea, OTC status, brand/generic marketing statements), and several safety/side-effect claims are only partially supported because the provided label mainly lists warnings (GI bleeding, cardiovascular thrombotic events) without the specific 'side effects' list including stroke/heart attack as adverse reactions.
Category Scores
Accurate Statements
Naproxen sodium is used to relieve pain.
Label 1 INDICATIONS & USAGE includes 'the management of: pain.'
Naproxen sodium is used to decrease inflammation.
Label 12.1 Mechanism of Action: Prostaglandins are mediators of inflammation; naproxen has analgesic, anti-inflammatory, and antipyretic properties.
Naproxen sodium is used to reduce fever.
Label 12.1 Mechanism of Action: naproxen has analgesic, anti-inflammatory, and antipyretic properties.
Naproxen sodium can reduce pain and swelling from inflammatory conditions.
Supported in concept by Label 12.1 stating anti-inflammatory and analgesic properties and that prostaglandins mediate inflammation; however, 'swelling' is not explicitly stated in the provided excerpt.
Naproxen sodium works by inhibiting the production of prostaglandins.
Label 12.1 Mechanism of Action: naproxen is a potent inhibitor of prostaglandin synthesis in vitro.
Prostaglandins contribute to inflammation, pain, and fever in the body.
Label 12.1: 'Prostaglandins are mediators of inflammation.' It also states prostaglandins sensitize afferent nerves and potentiate bradykinin in inducing pain in animal models; antipyretic/pain link to fever is not explicitly stated in the provided excerpt.
Unsupported Statements
Naproxen sodium is available as a generic medication marketed by multiple companies under various brand names.
The provided label excerpts do not discuss generic availability or marketing by multiple companies/brands.
Naproxen sodium is an over-the-counter (OTC) and prescription nonsteroidal anti-inflammatory drug (NSAID).
The provided label excerpts do not state OTC versus prescription availability.
Naproxen sodium is used to manage mild to moderate pain associated with menstrual cramps.
Label 1 lists 'primary dysmenorrhea' but does not specify 'mild to moderate' or the wording 'menstrual cramps' in the provided excerpt.
Naproxen sodium is used to manage mild to moderate pain associated with muscle aches.
Not supported by provided label indications; label lists pain generally and specific diseases, not 'muscle aches.'
Naproxen sodium is used to manage mild to moderate pain associated with headaches.
Not supported by provided label indications; 'headaches' not listed.
Naproxen sodium is used to manage mild to moderate pain associated with backaches.
Not supported by provided label indications; 'backaches' not listed.
Naproxen sodium is used to manage mild to moderate pain associated with arthritis.
While arthritis appears as 'rheumatoid arthritis' and 'osteoarthritis' in label, the claim is framed as a general 'mild to moderate pain associated with arthritis' indication and includes 'mild to moderate' which is not supported by the provided excerpt.
Naproxen sodium is used to manage mild to moderate pain associated with the common cold.
Not supported by provided label indications; 'common cold' not listed.
Naproxen sodium is widely recognized under the brand name Aleve.
The provided label excerpts do not mention the brand name Aleve.
Naproxen sodium has been available as a generic for many years.
The provided label excerpts do not discuss the duration of generic availability.
Common side effects of naproxen sodium can include stomach upset, heartburn, nausea, and dizziness.
The provided label excerpt 6 ADVERSE REACTIONS lists categories/warnings but does not enumerate these 'common side effects.'
More serious side effects of naproxen sodium may include gastrointestinal bleeding.
GI bleeding is mentioned as a topic in boxed warnings/warnings (GI bleeding, ulceration, perforation), but the claim is phrased as an adverse 'side effect' category; the excerpt does not provide an adverse reaction list including this item specifically.
More serious side effects of naproxen sodium may include heart attack.
Heart attack appears within boxed warning context as part of 'myocardial infarction' wording, but the claim is phrased as a general 'side effect' without explicit 'heart attack' wording in the excerpt.
More serious side effects of naproxen sodium may include stroke.
Stroke appears within boxed warning context as 'stroke'—however, the excerpt frames this as risk of cardiovascular thrombotic events; the statement is phrased as a side effect. The excerpt does not provide a direct adverse reaction list mapping.
More serious side effects of naproxen sodium may include kidney problems.
Renal toxicity and hyperkalemia are listed as warning topics in adverse reaction discussion, but the provided excerpt does not explicitly state 'kidney problems' as an adverse reaction.
Naproxen sodium should be used at the lowest effective dose for the shortest duration necessary.
The provided label excerpts include boxed warning text but do not include this specific dosing instruction.
Contradictions
Important Omissions
Specific dosing and administration details (e.g., dose, frequency, formulation-specific instructions) required to evaluate dosage alignment.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-related statements are not clearly supported by the provided label excerpts (e.g., 'common side effects' list, 'kidney problems' phrasing, and a specific dosing instruction). While boxed warning topics include cardiovascular thrombotic events and GI bleeding, the response uses imprecise 'side effect' framing and adds unverified details.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple claims (OTC status, brand recognition, general pain subtypes, and specific side-effect/dosing wording) are not supported by the provided prescribing information excerpts; safety statements are imprecise relative to the label’s warning topics.
Suggested Improvement
Limit claims to label-supported indications from the excerpt (e.g., rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendonitis, bursitis, acute gout; and management of pain and primary dysmenorrhea) and to label-supported mechanism and warning topics. Avoid asserting OTC status, Aleve brand familiarity, 'mild to moderate' qualifiers, and enumerated 'common side effects' unless present in the provided label.